News & Updates
Filter by Specialty:
Venetoclax-obinutuzumab ± ibrutinib induces PFS benefit in CLL
A time-limited regimen of venetoclax plus obinutuzumab with or without ibrutinib improved progression-free survival (PFS) in fit, treatment-naïve patients with chronic lymphocytic leukaemia (CLL), according to results of the phase III GAIA/CLL13 trial presented at EHA 2022.
Venetoclax-obinutuzumab ± ibrutinib induces PFS benefit in CLL
13 Jul 2022
Low vitamin D tied to lower risk of radiologic osteoarthritis in older men
A recent Korea study has found that low levels of vitamin D appear to be significantly protective against radiologic osteoarthritis (ROA) in older men but not women.
Low vitamin D tied to lower risk of radiologic osteoarthritis in older men
13 Jul 2022
Anaemia a major indication for obstetric red cell transfusion in multiethnic population
Red cell transfusion at a high-volume tertiary hospital in Singapore has an incidence of 3.2 percent in a multiethnic obstetric population, according to a study. Anaemia during pregnancy is the most common reason for transfusion administration.
Anaemia a major indication for obstetric red cell transfusion in multiethnic population
13 Jul 2022
Keto or Mediterranean diet for diabetes: Do we have a clear winner?
The ketogenic (keto) diet appears as good as the Mediterranean diet in reducing blood sugar in individuals with prediabetes, or type 2 diabetes (T2D), according to a small, randomized, crossover trial.
Keto or Mediterranean diet for diabetes: Do we have a clear winner?
13 Jul 2022
Dextromethorphan-bupropion relieves symptoms in major depressive disorder
Treatment with dextromethorphan-bupropion (AXS-05) significantly improves depressive symptoms relative to bupropion alone and is well tolerated in patients with major depression, results of a phase II trial have shown.
Dextromethorphan-bupropion relieves symptoms in major depressive disorder
13 Jul 2022
Ozoralizumab shows therapeutic potential in rheumatoid arthritis
Treatment with the next-generation anti-TNFα antibody yields marked improvements in the signs and symptoms of rheumatoid arthritis in patients with inadequate response to methotrexate (MTX), while having an acceptable safety profile, as shown in the phase II/III OHZORA trial.
